Opko Health, Inc. (OPK) Shares Sold by Parametric Portfolio Associates LLC

Parametric Portfolio Associates LLC trimmed its position in shares of Opko Health, Inc. (NASDAQ:OPK) by 11.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,074 shares of the biotechnology company’s stock after selling 14,231 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Opko Health were worth $718,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in OPK. Lehman Financial Resources Inc. increased its stake in shares of Opko Health by 7.4% in the 2nd quarter. Lehman Financial Resources Inc. now owns 261,668 shares of the biotechnology company’s stock worth $1,737,000 after purchasing an additional 18,075 shares in the last quarter. Old West Investment Management LLC increased its stake in shares of Opko Health by 36.9% in the 2nd quarter. Old West Investment Management LLC now owns 54,805 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 14,759 shares in the last quarter. California Public Employees Retirement System increased its stake in shares of Opko Health by 2.2% in the 2nd quarter. California Public Employees Retirement System now owns 779,356 shares of the biotechnology company’s stock worth $5,128,000 after purchasing an additional 16,900 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Opko Health by 1.1% in the 2nd quarter. Vanguard Group Inc. now owns 26,618,758 shares of the biotechnology company’s stock worth $175,151,000 after purchasing an additional 296,757 shares in the last quarter. Finally, Van ECK Associates Corp increased its stake in shares of Opko Health by 19.6% in the 2nd quarter. Van ECK Associates Corp now owns 100,468 shares of the biotechnology company’s stock worth $661,000 after purchasing an additional 16,484 shares in the last quarter. 22.33% of the stock is currently owned by hedge funds and other institutional investors.

In other Opko Health news, major shareholder Opko Health, Inc. purchased 655,738 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was purchased at an average price of $3.05 per share, with a total value of $2,000,000.90. Following the acquisition, the insider now owns 6,678,752 shares in the company, valued at $20,370,193.60. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Phillip Md Et Al Frost purchased 25,000 shares of the stock in a transaction that occurred on Friday, August 25th. The stock was acquired at an average cost of $6.17 per share, with a total value of $154,250.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $18,935,427.67. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 1,087,238 shares of company stock valued at $4,591,446. Company insiders own 40.19% of the company’s stock.

OPK has been the subject of a number of analyst reports. Jefferies Group LLC reiterated a “hold” rating and issued a $8.00 price target on shares of Opko Health in a research note on Thursday, July 27th. BidaskClub lowered Opko Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research lowered Opko Health from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. Cantor Fitzgerald initiated coverage on Opko Health in a research note on Thursday, August 17th. They issued an “overweight” rating and a $20.00 price target for the company. Finally, J P Morgan Chase & Co lowered Opko Health from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $12.00 to $7.00 in a research note on Thursday, September 14th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. Opko Health presently has a consensus rating of “Hold” and a consensus target price of $13.97.

Shares of Opko Health, Inc. (NASDAQ OPK) opened at $4.78 on Wednesday. The company has a quick ratio of 1.48, a current ratio of 1.66 and a debt-to-equity ratio of 0.01. Opko Health, Inc. has a 12 month low of $4.50 and a 12 month high of $12.15.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.05) by ($0.03). The firm had revenue of $263.50 million for the quarter, compared to analysts’ expectations of $319.43 million. Opko Health had a negative net margin of 9.45% and a negative return on equity of 5.17%. The company’s revenue for the quarter was down 11.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.03) EPS. sell-side analysts predict that Opko Health, Inc. will post -0.27 EPS for the current fiscal year.

WARNING: This news story was first reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://transcriptdaily.com/2017/11/22/opko-health-inc-opk-shares-sold-by-parametric-portfolio-associates-llc.html.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health, Inc. (NASDAQ:OPK).

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply